title: Does the surface-treated AN69 membrane prolong filter survival in CRRT without anticoagulation?
abstract: OBJECTIVE
  The need for continuous anticoagulation remains a significant drawback in continuous renal replacement therapy (CRRT), especially in patients with increased bleeding risk. Polyethyleneimine treatment of the AN69 membrane (AN69ST) reduces thrombogenicity through decreased contact activation and promotion of heparin binding. The aim of this study is to evaluate whether this membrane prolongs filter survival in CRRT without anticoagulation.
  
  
  METHODS
  A single-center, prospective, randomized, double-blind controlled trial with cross-over design comparing filter survival with the AN69ST membrane and the original AN69 membrane in 39 patients treated with continuous venovenous hemofiltraton (CVVH) without additional heparin.
  
  
  RESULTS
  Filter survival with the AN69ST membrane (n = 75) was 14.2 ± 8.2 h, which is not significantly different from the 13.3 ± 10.3 h for the original AN69 membrane (n = 76; p = 0.59). Limiting the analysis to those treatments that were interrupted for filter clotting yielded similar results: 14.4 ± 8.2 h for the AN69 ST membrane (n = 62) versus 14.1 ± 7.5 h for the original AN69 membrane (n = 56) (p = 0.93).
  
  
  CONCLUSIONS
  Compared with the original AN69 membrane, the surface-treated AN69ST membrane does not prolong filter survival during CVVH without systemic anticoagulation and with the CRRT settings used in this study.
authors: Department of Intensive Care Medicine, University Hospital of the Catholic University Leuven, Herestraat 49, 3000, Leuven, Belgium. marie.schetz@uzleuven.be
authors: Miet
authors: M
authors: Schetz
authors: Sophie
authors: S
authors: Van Cromphaut
authors: Jasperina
authors: J
authors: Dubois
authors: Greet
authors: G
authors: Van den Berghe
mesh_terms: D000180:Acrylic Resins; D020099:Coated Materials, Biocompatible; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004867:Equipment Design; D005260:Female; D005343:Fibrinolytic Agents / Q000493:pharmacokinetics; D006440:Hemofiltration / Q000295:instrumentation*; D006493:Heparin / Q000493:pharmacokinetics; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008567:Membranes, Artificial; D008875:Middle Aged; D011094:Polyethyleneimine; D011446:Prospective Studies
chemical_list: D000180:Acrylic Resins; D020099:Coated Materials, Biocompatible; D005343:Fibrinolytic Agents; D008567:Membranes, Artificial; C010504:polyacrylonitrile; D011094:Polyethyleneimine; D006493:Heparin